Composition for the reduction of side-effects of dopaminergic agents

A composition utilizing a nicotinic receptor modulator, to reduce or eliminate a side effect associated with dopaminergic agent treatment. The composition is a solid unit dosage form that comprises 6mg or less nicotine and a pharmaceutically acceptable excipient. Preferably the unit dosage form comprises 3mg or less nicotine.

Use of a nicotinic receptor agonist in the treatment of dyskinesias associated with dopaminergic agent therapy

A nicotine receptor agonist, for example nicotine, may be used in the treatment of dyskinesias associated with dopaminergic agent therapy. This is especially useful in the treatment of Parkinson's disease with L-DOPA where the side-effect of dyskinesias brought about by administration of L-DOPA are reduced. The nicotine receptor agonist and dopaminergic agent may be used in conjunction with a third agent to achieve a therapeutic effect with the said dopaminergic agent or for treatment of a side-effect of the said dopaminergic agent. The third agent may be amantadine, carbidopa or entacapone.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic rec eptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides co mpositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect assoc iated with dopaminergic agent treatment.

Methods and compositions for reduction of side effects of therapeutic treatments

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent

Methods and compositions for reduction of side effects of therapeutic treatments

Methods and compositions for reduction of side effects of therapeutic treatments

Methods and compositions for reduction of side effects of therapeutic treatments

Methods and compositions for reduction of side effects of therapeutic treatments

Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like

Compositions and methods are provided for utilizing a nicotinic receptor modulator to reduce or eliminate side effects associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. As an example, nicotine may be used in combination with levodopa to treat Parkinson's disease with reduced dyskinesia.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Methods and compositions for reduction of side effects of therapeutic treatments

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Methods and compositions for reduction of side effects of therapeutic treatments

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. 1152-. (canceled)153. A method for reducing dopaminergic agent-induced dyskinesia comprising administering orally to a human being treated with said dopaminergic agent an amount of nicotine sufficient to reduce dyskinesia induced by said dopaminergic agent , wherein said amount of nicotine is administered such that nicotine or a nicotine metabolite reaches a critical concentration of about 1 ng/ml to about 20 ng/ml , and wherein the amount of nicotine is less than 24 mg per day.154. The method of claim 153 , wherein said critical concentration is reached about one hour to about three hours after the dopaminergic agent reaches the bloodstream or brain.155. The method of claim 153 , wherein said critical concentration is reached about one hour to about three hours before the dopaminergic agent reaches the bloodstream or brain.156. The method of claim 153 , wherein said critical concentration is reached at from about one hour to about a minute before the dopaminergic agent-induced dyskinesia reaches a peak.157. The method of claim 153 , wherein the amount of nicotine is sufficient to reduce said dyskinesia at least about 30%.158. The method of claim 153 , wherein said dyskinesia is induced by a Parkinson's disease treatment.159. The method of claim 153 , wherein said dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist.160. The method of claim 153 , wherein said dopaminergic agent comprises levodopa claim 153 , bromocriptine claim 153 , pergolide claim 153 , pramipexole claim 153 , cabergoline claim 153 , ropinirole claim 153 , ...

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Methods and compositions for reduction of side effects of therapeutic treatments

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. 1152.-. (canceled)153. A method of treating a dopaminergic-agent induced dyskinesia in a subject comprising administering transdermally and discontinuously to the subject a controlled amount of a composition comprising nicotine or other nicotinic receptor agonist.154. The method of wherein the composition further comprises a dopaminergic agent.155. The method of further comprising performing the administering step 1-6 times per day.156. The method of wherein the administering step comprises transdermally and discontinuously administering the controlled amount of the composition via pulsatile delivery.157. The method of wherein the composition further comprises a dopaminergic agent.158. The method of further comprising performing the administering step 1-6 times per day.159. The method of wherein the administering step comprises transdermally and discontinuously administering the controlled amount of the composition via a patch.160. The method of wherein the composition further comprises a dopaminergic agent.161. The method of further comprising performing the administering step 1-6 times per day.162. The method of wherein the administering step comprises transdermally and discontinuously administering the controlled amount of the composition via a minipump.163. The method of wherein the composition further comprises a dopaminergic agent.164. The method of further comprising performing the administering step 1-6 times per day. This application is a continuation of U.S. patent application Ser. No. 14/850,840, filed Sep. 10, 2015, which is a continuation of ...

Neuronal nicotinic agonists and methods of use

An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor 7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor 7 subtype, or a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof.

Methods and compositions for reduction of side effects of therapeutic treatments

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Methods and compositions for reduction of side effects of therapeutic treatments

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Methods and compositions for reduction of side effects of therapeutic treatments